Pharmaterials has invested in a new dedicated 30,000 sq ft facility, which will be fitted out to enable the company to offer GMP manufacture for Phase I clinical trials, with specific expertise in inhalation and oral dose forms.
Located in Reading, the UK company expects the facility to be ready to begin manufacturing early in 2009 Pharmaterials.
Professor Graham Buckton, ceo of Pharmaterials, said "Our investment in new facilities and state of the art equipment will allow the true potential of our team to be realised. Pharmaterials will be positioned to take our customers new molecules in to the clinic in the shortest possible time, meeting the pressures of today's drug development."
Pharmaterials is currently a contract research organisation providing state-of-the-art service provision in polymorphism screening, salt selection, co-crystal formation, amorphous materials characterisation, preformulation and physico-chemical testing.
In the formulation area the company provides solutions to poorly soluble drug formulation and inhaled drug delivery and can provide material for studies through to Phase I.
Pharmaterials was acquired by PII, the Baltimore based contract formulation and manufacturing company, in January 2008. PII manufactures solid oral, semi-solid and liquid dosage forms (tablets, hard and soft gelatin capsules, pellets sustained release products etc) as well as aseptic vial filling.
